Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03611621 · ClinicalTrials.gov registry record
A Follow up Study of Patients Treated With Imlifidase Prior to Kidney Transplantation
A clinical trial, sponsored by Hansa Biopharma AB.
- Completed
- Registry status
- 31
- Enrollment target
NCT03611621: Completed study, sponsored by Hansa Biopharma AB.
NCT03611621 is a clinical trial that has completed, run by Hansa Biopharma AB. The registered enrollment target is 31 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03611621 has completed, sponsored by Hansa Biopharma AB.
- COMPLETED
- Registry status
- 31 participants
- Enrollment target
Study Summary
The rationale for the current protocol is to collect data from extended follow up in subjects that have received a kidney transplant following imlifidase dosing to provide a better understanding regarding the long-term outcome for these subjects. Data of parameters such as patient and graft survival, comorbidity, treatment of graft rejection episodes and quality of life as well as anti-drug antibody levels will be collected. This prospective, observational follow up study of subjects who have received imlifidase prior to kidney transplantation will provide important data to future prescribers and patients of the potential long-term benefits of imlifidase mediated transplantation.
Primary Outcome
The primary endpoint of this study is to determine overall graft survival, defined as time from transplantation to graft loss.
Interventions
- DRUG Imlifidase
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2018-06-27 |
| Est. Completion | 2023-02-14 |
What the finished NCT03611621 record still lists
NCT03611621 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 31 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Imlifidase is the first listed.
NCT03611621 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03611621 about?
NCT03611621 is a clinical study titled "A Follow up Study of Patients Treated With Imlifidase Prior to Kidney Transplantation". The rationale for the current protocol is to collect data from extended follow up in subjects that have received a kidney transplant following imlifidase dosing to provide a better understanding regarding the long-term outcome for these subjects. Data of parameters such as patient and graft survival...
What is the current status of trial NCT03611621?
This trial is currently completed. The enrollment target is 31 participants. The study started on 2018-06-27. Estimated completion is 2023-02-14.
What interventions are being tested in trial NCT03611621?
The interventions under investigation include: Imlifidase (DRUG).
Who is sponsoring clinical trial NCT03611621?
This trial is sponsored by Hansa Biopharma AB, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI